A Retrospective Controlled Survey Study to Assess the Safety of Treating Migraine With Nerivio During Pregnancy and 3 Months Postpartum
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 145
- 试验地点
- 2
- 主要终点
- Gestational Age at Delivery
研究概览
简要总结
This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group). Nerivio group participants will be recruited from Theranica's user base. Control group participants will be recruited by health care providers, including headache specialists and OBGYNs (study co-investigators). The study is based on an e-Survey including an e-eligibility questionnaire, an e-ICF ande-Questionnaire. Participants will be compensated for their time.
详细描述
This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group).
Study group: Study group participants will be recruited from Nerivio's user base. An invitation message will be sent via in-app notification and/or email to all Nerivio users who are (1) female, AND (2) between 18 and 42 years of age as of November 1st, 2019 - March 31st, 2021. Users who meet these criteria will be invited to fill in a screening and eligibility questionnaire. If they meet the eligibility criteria, they will be offered the opportunity to participate in the study. Participants will complete and sign an electronic informed consent form. Following consent, participants will be asked to complete the questionnaire. Once complete, participants will be compensated for their time.
Control group: Control group participants will be referred to the study by site co-investigators, who are US-licensed healthcare providers seeing women with headache disorders and/or women during their pre-pregnancy and/or pregnancy period. Patients interested in participating will be directed to the same screening and eligibility questionnaire and will follow the same study design.
Endpoints focus on the health of the mother and the baby, during pregnancy and three months postpartum.
Primary endpoint:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 42 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Diagnosed with migraine
- •History of migraine pre-pregnancy with an average of at least 4 migraine days per month, in the six months prior to the last pregnancy
- •History of pregnancy with last menstrual period (LMP) between November 1st, 2019 - March 31st,
- •Pregnancy within this time window is the pregnancy of study, termed "study pregnancy"
- •Between 18 and 42 years of age at first day of the last menstrual period (LMP) of "study pregnancy"
- •History of at least 4 migraine attacks during "study pregnancy"
- •In the study group: usage of Nerivio for at least 3 treatments (≥30 minutes/treatment) during "study pregnancy"
- •In the control group: No history of using Nerivio, ever
排除标准
- •History of preterm birth (gestational age at deliver<37 weeks) in previous pregnancies prior to the "study pregnancy"
- •History of congenital malformations or birth defects in previous pregnancies prior to the "study pregnancy"
- •Severe other diseases which started before the "study pregnancy" and lasted into the "study pregnancy" period, including congenital heart disease, arrhythmia, history of myocardial infarction (MI), history of stroke, or active cancer
- •Serious physical injury that occurred during the "study pregnancy": severe car collision injury, serious injury at home/work, etc. Multiple gestation (i.e., pregnancy with more than one baby at a time, such as pregnancy with twins, triplets, and quadruplets) in the "study pregnancy"
研究组 & 干预措施
Postpartum females with migraine who used Nerivio during their pregnancy
Postpartum patients with migraine who used Nerivio at least 3 times during their pregnancy. Participants will be recruited from Nerivio's user database
干预措施: Nerivio (Device)
Postpartum females with migraine who used other migraine therapy during their pregnancy
Postpartum patients with migraine who did not used Nerivio prior and during their pregnancy, and at least 3 months postpartum. Participants will be referred to the study by site co-investigators, who are US-licensed healthcare providers seeing women with headache disorders and/or women during their pre-pregnancy and/or pregnancy period
干预措施: Migraine Relief (Drug)
结局指标
主要结局
Gestational Age at Delivery
时间窗: Retrospective Data for up to 42 weeks, collected over 2 months
The mean number of gestational age at delivery in both study groups (measured in pregnancy days).
次要结局
- Developmental Milestones Rate Following 3 Months Postnatal(Retrospective Data for up to 55 weeks, collected over 2 months)
- Migraine Patterns(Retrospective Data for up to 55 weeks, collected over 2 months)
- Birth Weight(Retrospective Data for up to 42 weeks, collected over 2 months)
- Miscarriage Rate(Retrospective Data for up to 42 weeks, collected over 2 months)
- Preterm Birth Rate(Retrospective Data for up to 42 weeks, collected over 2 months)
- Birth Deficits Rate(Retrospective Data for up to 42 weeks, collected over 2 months)
- Still Births Rate(Retrospective Data for up to 42 weeks, collected over 2 months)